Pictet North America Advisors’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-5,430
Closed -$660K 130
2023
Q2
$660K Buy
5,430
+136
+3% +$18.1K 0.09% 96
2023
Q1
$813K Buy
+5,294
New +$873K 0.13% 83

Other funds holding MRNA

Pictet North America Advisors's MRNA Position: Q3 2023 in Review

Pictet North America Advisors sold out of Moderna (MRNA) in Q3 2023, closing a stake of 5,430 shares — an estimated $660K sold.

Pictet North America Advisors first reported a position in MRNA in Q1 2023 and held it in 2 quarters. The position peaked at $813K in Q1 2023. 890 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Pictet North America Advisors reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Pictet North America Advisors sold 5,430 Moderna shares in Q3 2023, an estimated $660K.
  • Pictet North America Advisors first reported a position in Moderna in Q1 2023 and held it in 2 quarters.
  • Pictet North America Advisors's Moderna position peaked at $813K in Q1 2023.
  • 890 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Pictet North America Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.